Edelman has created a dedicated unit to boost its biotechnology and
pharmaceutical client list.
The venture, called Biro, will draw on as many as 35 staff from
Edelman's financial and healthcare divisions with the aim of offering
clients better global lines of communication between financial,
scientific and healthcare professionals.
Its key targets include established companies and also entrepreneurs and
investors looking to break into the sector.
The venture is headed by healthcare head Nigel Breakwell and director
According to Henman, the plan involves more than simply renaming
existing services under the banner of a 'one-stop shop'.
He said: 'We are positioning our services in a way that is more readily
accessible to the clients in meeting their needs.
'If you are an entrepreneur with a great idea in biotechnology or
pharmaceutical areas and you decide you want to build your business two
key elements you need are someone with financial intelligence and
contact with those in the industry such as distributors.'
Two companies have already been taken on. Under the Biro name, staff at
Edelman have started work for Oxford Bio Signals, which collects data
from brain scans and Tristem, which works in the haematology field.
The venture follows recent changes in the agency's financial division
earlier this year. In February, Henman quit rival city PR firm
Grandfield, where he was a founding director, to join Edelman (PRWeek, 9
He was joined by Grandfield's head of plc and corporate Stephen
Benzikie, who now leads the division, as part of a double swoop designed
to revitalise the 20-strong team. Previously Edelman London MD John
Mahony had acted as head of its financial practice.
Biro was officially launched at an event held in Cambridge last week.